Last reviewed · How we verify
NCT06907563: LOVE
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
trial in Steatotic Liver Disease in 30,000 participants. Not yet recruiting.
31 December 2030
Quick facts
| Lead sponsor | Universität des Saarlandes |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30,000 |
| Start date | 15 April 2025 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2035 |
| Sites | 4 locations across France, United Kingdom, Germany, Italy |
Conditions studied
- Steatotic Liver Disease — all drugs for Steatotic Liver Disease →
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) — all drugs for MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) →
- Steatotic Liver Disease of Mixed Origin (MetALD) — all drugs for Steatotic Liver Disease of Mixed Origin (MetALD) →
- ALD - Alcoholic Liver Disease — all drugs for ALD - Alcoholic Liver Disease →
Sponsor
Universität des Saarlandes — full company profile →
Who can join
18 and older, any sex, with Steatotic Liver Disease or MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06907563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Steatotic Liver Disease
Currently open trials in the same condition.
- NCT06823713 — RTX001 Autologous Engineered Macrophages for Liver Cirrhosis · Phase 1, PHASE2 · recruiting
- NCT04721665 — German SLD-Registry (Deutsches SLD-Register) · recruiting
Other Universität des Saarlandes trials
Trials by the same sponsor.
- NCT07530809 — Time-restricted Feeding in MASLD · NA · recruiting
- NCT06865950 — Sex diffErences in prehoSpitAl Stroke MEdicine · recruiting
- NCT06453577 — Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure · active not recruiting
- NCT06459115 — Adherence to Medication in Patients With Acute Decompensated Heart Failure · recruiting
- NCT05651464 — Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06907563 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität des Saarlandes
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06907563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing